Form 4 for PLX Protalix BioTherapeutics, Inc.
Accepted 2025-08-12 00:00:00 ET · period of report 2025-06-10 · accession 0001415889-25-021494 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-12 | 2025-06-10 | PLX | Schwartz Aharon | Dir | P - Purchase | $1.60 | +129.0K | 303.0K | +74% | +$206.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-10 | P | A | 129,000 | $1.60 | 303,000 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $1.60 to $1.575 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |